compounded semaglutide not losing weight Why Am I on Semaglutide? why am i not losing

Maintenance: 12 mg once weekly or maintain at 8 mg , depending on research goals and tolerability

It belongs to the GLP-1 class but represents the third generation of that class

The expected timeline: Phase 3 trials completing: Results rolling out throughout the rest of this year FDA submission: Expected sometime after full Phase 3 data is available Potential FDA approval: Estimated for late 2027 at the earliest Commercial availability: If approved, launch would follow in 2027-2028 For those tracking retatrutide availability updates , the situation is evolving

During this transition, customers may receive inventory labeled as either the GLP-1 Support Patch or the Berberine Patch while packaging updates are completed